US court overturns Insulet’s $452 million insulin-pump trade secret verdict against EOFlow

By Blake Brittain

WASHINGTON, May 28 (Reuters) – A U.S. appeals court ​on Thursday ‌overturned a $452 million verdict that medical device maker Insulet won against ‌Korean ​rival ⁠EOFlow for allegedly ⁠stealing trade secrets related to its insulin-pump technology.

The Washington-based U.S. ​Court of Appeals for the ⁠Federal Circuit ⁠reversed the verdict ​after finding that ​Insulet had waited too ‌long to bring its lawsuit.

A federal jury in Massachusetts ⁠had determined in 2024 that EOFlow owed $452 million ⁠in ‌damages for misappropriating ⁠Insulet trade ​secrets ‌to create a ​competitor to ⁠Insulet’s Omnipod, a wearable insulin pump for diabetes patients.

(Reporting by Blake Brittain in ​Washington)